Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUC398 in Symptomatic Knee Osteoarthritis
NCT05462990Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of QUC398 in osteoarthritis (OA), sponsored by Novartis. Started Nov 2022; status: terminated.
02
Drugs
QUC398
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05462990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462990.